Please assess the completion status of the following clinical trial:

Trial Title: Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with stage I-IV non-small cell lung cancer(with no restriction of age, gender, or smoking history)~* Patients in the group will be allowed to collect whole blood and tissue samples at specific time points~* Eastern Cooperative Oncology Group Performance Status of 0-1 within 28 days prior to registration~* No previous systemic anti-tumor therapy~* Signed informed consent~Exclusion Criteria:~* Active or history of autoimmune disease or immune deficiency~* Patients with serious mental disease~* Prior allogeneic stem cell or solid organ transplantation~* Pregnant or lactating women~* Patients who cannot obtain tumor tissue samples and / or whole blood~* Patients with history of blood transfusion within half a year~* Patients with any other malignancy diagnosed within 5 years~* Received systemic anti-tumor therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).